Compare Prologis Inc (PLD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Smith & Nephew plc — how do they compare? Prologis Inc trades at $128.94 (market cap $122.87B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Prologis Inc is far larger — about 11.1× Smith & Nephew plc's market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Smith & Nephew plc for 120 Days on average.
| PLD | SNN | |
|---|---|---|
Market Cap | $122.87B | $11.10B |
Volume | 4,222,957 | 1,051,703 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $37.17 |
52-Week Low | $111.23 | $26.42 |
Typical Hold Time | 102 Days | 120 Days |
Enterprise Value | $157.61B | $14.13B |
Dividend Yield | 3.31% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $127.3, down 1.07% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and three consecutive quarterly EPS beats. The stock is supported by robust cash flow from operations of $5.01B in 2025 and positive leasing momentum highlighted by management. Recent news emphasizes growth from warehouse and data center demand, though technical indicators show selling pressure with key support at $126.
The outlook is mixed: analyst consensus is bullish with a $155.15 price target (59.52% buy ratings), but rising debt-to-asset ratios and bearish moving averages pose risks. Upside hinges on continued execution in logistics real estate, while macroeconomic sensitivity and valuation premiums require monitoring for sustained shareholder returns.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
